The ADXS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ADXS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ADXS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ADXS Detailed Price Forecast - CNN Money||View ADXS Detailed Summary - Google Finance|
|View ADXS Detailed Summary - Yahoo! Finance||View ADXS Stock Research & Analysis - Zacks.com|
|View ADXS Trends & Analysis - Trade-Ideas||View ADXS Major Holders - Barrons|
|View ADXS Call Transcripts - NASDAQ||View ADXS Breaking News & Analysis - Seeking Alpha|
|View ADXS Annual Report - CompanySpotlight.com||View ADXS OTC Short Report - OTCShortReport.com|
|View ADXS Fundamentals - TradeKing||View ADXS SEC Filings - Bar Chart|
|View Historical Prices for ADXS - The WSJ||View Performance/Total Return for ADXS - Morningstar|
|View the Analyst Estimates for ADXS - MarketWatch||View the Earnings History for ADXS - CNBC|
|View the ADXS Earnings - StockMarketWatch||View ADXS Buy or Sell Recommendations - MacroAxis|
|View the ADXS Bullish Patterns - American Bulls||View ADXS Short Pain Metrics - ShortPainBot.com|
|View ADXS Stock Mentions - StockTwits||View ADXS Stock Mentions - PennyStockTweets|
|View ADXS Stock Mentions - Twitter||View ADXS Investment Forum News - Investor Hub|
|View ADXS Stock Mentions - Yahoo! Message Board||View ADXS Stock Mentions - Seeking Alpha|
|View Insider Transactions for ADXS - SECform4.com||View Insider Transactions for ADXS - Insider Cow|
|View ADXS Major Holdings Summary - CNBC||View Insider Disclosure for ADXS - OTC Markets|
|View Insider Transactions for ADXS - Yahoo! Finance||View Institutional Holdings for ADXS - NASDAQ|
|View ADXS Stock Insight & Charts - FinViz.com||View ADXS Investment Charts - StockCharts.com|
|View ADXS Stock Overview & Charts - BarChart||View ADXS User Generated Charts - Trading View|
Advaxis Shares Climb After FDA Lifts Partial Clinical Hold On Cervical Cancer Drug
Posted on Wednesday May 15, 2019
Nanocap Advaxis, Inc. (NASDAQ: ADXS ) is seeing strength Wednesday following an announcement concerning its cervical cancer drug. What Happened Advaxis announced the lifting of a partial clinical hold ...
FDA Lifts Partial Clinical Hold on Phase 3 AIM2CERV Study of Axalimogene Filolisbac
Posted on Wednesday May 15, 2019
Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.S. Food and Drug Administration (FDA or Agency) has lifted the partial clinical hold on AIM2CERV, the company’s Phase 3 clinical trial of axalimogene filolisbac (AXAL) for the treatment of patients with high-risk locally advanced cervical cancer. In its letter, the FDA acknowledged that the company satisfactorily addressed all hold questions. As announced on January 23, 2019, the FDA placed a partial clinical hold on this study relating to the Agency’s requests for additional information pertaining to certain AXAL chemistry, manufacturing and controls (CMC) matters. The Agency did not cite any safety issues related to the trial and all enrolled patients continued to receive treatment, per the trial protocol.
Advaxis Announces Two Poster Presentations at the Frontiers in Cancer Immunotherapy Conference
Posted on Tuesday May 14, 2019
Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of two posters at the Frontiers in Cancer Immunotherapy conference, being held today at the New York Academy of Sciences in New York City. Both posters were first presented at the recent American Association for Cancer Research (AACR) Annual Meeting, and each has updated findings being presented today. The first presentation regarding a poster entitled “Effects of ADXS-PSA With or Without Pembrolizumab on Survival and Antigen Spreading in Metastatic, Castration-Resistant Prostate Cancer Patients (Results from KEYNOTE-046)” is conference poster #31, and will be presented by Robert Petit, Ph.D., Advaxis Chief Scientific Officer, and Mark N. Stein, M.D., FACS, Associate Professor of Medical Oncology at Columbia University Medical Center, from 4:45 to 5:30 p.m. Eastern time.
Advaxis, Inc. (ADXS) (the “Company”), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Robert Petit, Ph.D. will be leaving his position as Chief Scientific Officer at the end of the month. Dr. Petit will assist the Company in transitioning his duties over the next several weeks, and will continue to support the Company as an advisor and consultant in his capacity as the new Chair of the Advaxis Scientific Advisory Board, effective June 3, 2019.